Skip to content

Effect of Ginseng on Glycemic Control

Effect of Ginseng on Glycemic Control: A Systematic Review and Meta-analysis of Controlled Trials to Provide Evidence-based Clinical Recommendations

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01841229
Enrollment
770
Registered
2013-04-26
Start date
2012-10-31
Completion date
2013-05-31
Last updated
2013-05-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes, Impaired Glucose Tolerance

Brief summary

Ginseng (American ginseng, Asian ginseng, Korean ginseng etc) is expected to show positive hypoglycemic effects, including improvements in glycated blood proteins\[HbA1c\], fasting glucose, fasting insulin, and the homeostasis model assessment of insulin resistance \[HOMA-IR\]).

Detailed description

Ginseng has demonstrated to have significant hypoglycemic effect. Its major pharmacological component is considered to be ginsenosides. Several trials have been undertaken in diabetes some of which have demonstrated advantages in glycemic control in both diabetic as well as non diabetic individuals although clinical consistency of results is lacking.The lack of high quality data in this area to support diabetes recommendations represents an urgent call for stronger evidence. A systematic review and meta-analysis of controlled trials remains the Gold Standard of evidence for recommendations and clinical guidelines development. Therefore, investigators will conduct a systematic review and meta-analyses of controlled trials to assess the effect of ginseng on glycemic control.

Interventions

None listed

Sponsors

Unity Health Toronto
Lead SponsorOTHER

Eligibility

Sex/Gender
ALL
Healthy volunteers
Yes

Inclusion criteria

* Dietary trials in humans * Randomized treatment allocation * 1 month * Suitable control * Viable endpoint data

Exclusion criteria

* Non-human studies * Non-randomized treatment allocation * \<1 month * Lack of a suitable control * No viable endpoint data

Design outcomes

Primary

MeasureTime frame
Glycated hemoglobin (HbA1c)1month

Secondary

MeasureTime frame
Fasting blood glucose1month
Fasting plasma insulin1 month
Homeostasis model assessment of insulin resistance (HOMA-IR)1 month

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 19, 2026